A Pilot Study to Assess the Effects of Doxazosin on Polysomnography in PTSD

Exclusion Criteria

• •1. alcohol and or drug abuse/dependence in the last 3 months
• •2. lifetime history of any psychiatric disorder with psychotic features, bipolar disorder, obsessive-compulsive disorder
• •3. exposure to trauma within the last 3 months
• •4. prominent suicidal or homicidal ideation
• •5. sleep apnea diagnosis or positive screen for sleep apnea by Type III device.
• •6. neurologic disorder or systemic illness affecting CNS function
• •7. history of brain trauma or head injury with loss of consciousness greater than 10 minutes
• •8. chronic or unstable medical illness including unstable angina, myocardial infarction within the past 6 months, congestive heart failure, preexisting hypotension or orthostatic hypotension, chronic renal or hepatic failure, and pancreatitis
• •9. pregnancy, breastfeeding and/or refusal to use effective birth control
• •10. previous serious adverse reaction to an alpha-1-antagonist (such as priapism, hepatitis, angioedema, or intraoperative floppy iris syndrome)
• •11. current use of trazodone, hypnotics/benzodiazepines, mirtazapine, atypical antipsychotics, beta-adrenergic blockers, alpha-2-agonists, and current prazosin or other alpha-1-antagonists
• •12. previous non-response to prazosin for treatment of PTSD related sleep disturbance
• •Participants taking SSRIs, bupropion, venlafaxine and duloxetine may be included if they have been on a stable dose for 2 months. Participants may be included if they have been stable in psychotherapy treatment for 2 months and/or if they begin no new psychotherapy while in the trial.